Cell Pathways And Squibb Agree Joint Study

Cell Pathways, Inc. and Company plan to cooperate in supporting a clinical trial to study the combination of Aptosyn (exisulind) and TAXOL (paclitaxel) plus Paraplatin (carboplatin) as a first-line treatment for patients with advanced non- small cell lung cancer (NSCLC). This Phase I/II study is designed to evaluate escalating doses of Aptosyn in combination with a standard regimen of TAXOL plus Paraplatin.

The two companies intend to share the costs of this effort and share information.

“Our selective apoptotic anti-neoplastic drugs (SAANDs), including Aptosyn, have demonstrated synergistic anti-cancer effects in preclinical studies when combined with taxanes including TAXOL,” said Rifat Pamukcu, M.D., chief scientific officer of Cell Pathways.

“This new study extends the breadth of our current clinical investigations by using Aptosyn in combination with chemotherapeutic agents commonly used as first-line treatment in patients with NSCLC.

This is an indication where current treatment options are limited, and it is our hope that this drug combination may eventually demonstrate improvement in survival in this high mortality disease.”

Cell Pathways’ lead drug candidate, Aptosyn, is an investigational, oral agent that is designed to selectively trigger programmed cell death, or apoptosis, in precancerous and cancer cells via a mechanism of action different from currently marketed chemotherapeutic agents.

The combination of Bristol-Myers Squibb’s TAXOL and Paraplatin is the most commonly used regimen in community practice for the first-line treatment of NSCLC.

Cell Pathways, Inc., headquartered in Horsham, is a development stage pharmaceutical company focused on the research, development and commercialisation of novel and unique medications to prevent and treat cancer.

Procure Dragon Pharma LLC Online

Masteron 100 - Bulk Price

Administration: Injection
Basal Component: Drostanolone Di-Propionate
Made by: Dragon Pharmaceutical
Pack: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $49.00

Propionat 100 - Bulk Price

Administration: Injection
Basal Chemical Name: Testosterone Propionate
Produced by: Dragon Pharmaceutical
Amount: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $30.00

Winstrol Tabs - Bulk Price

Administration: Oral
Primary Constituent: Stanozolol
Made by: Dragon Pharma
Amount: 10 x 100 tabs (50 mg/pill)
Price: 10 x $63.00

Cypionat 250

Injectable Anabolic Steroid
Primary Constituent: Testosterone Cypionate
Made by: Dragon Pharma
Unit: 1 X 10 ml (250 mg/ml)

Dianabol

Natural Anabolic Steroidal Agent
Base Ingredient: Methandrostenolone
Branded by: Dragon Pharma
Package: 1 X 100 tabs (20 mg/tab)

Cypionat 250 - Bulk Price

Administration: Injection
Main Constituent: Testosterone Cypionate
Made by: Dragon Pharma Labs
Pack: 10 x 10 mL vial (250 mg/mL)
Price: 10 x $36.00

Clenbuterol

Primary Chemical Name: Clenbuterol Hydrochloride
Branded by: Dragon Pharmaceuticals
Pack: 100 tabs (40 mcg/tablet)

Tritren 150 [10 Vials]

Injectable Steroid for Muscle Growth
Mix of:
- 50mg of Trenbolone Acetate
- 50mg of Trenbolone Enanthate
- 50mg of Trenbolone Hexahydrobenzylcarbonate
Manufacturer: Dragon Pharmaceuticals
10 Vials [10 mL per Vial (150 mg/ml)]
Price: 10 x $72.00 = $720.00 in Total

EQ 300 [10 Vials]

Injectable Steroid for Muscle Growth
Basic Ingredient: Boldenone Undecylenate
Manufacturer: Dragon Pharmaceutical
10 Vials [10 mL per Vial (300 mg/ml)]
Price: 10 x $42.00 = $420.00 in Total

Parabolan 100 [10 Vials]

Injectable Steroid for Muscle Growth
Base Component: Trenbolone Hexahydrobenzylcarbonate
Producer: Dragon Pharmaceutical
10 Vials [10 mL per Vial (100 mg/ml)]
Price: 10 x $69.00 = $690.00 in Total

Cypionat 250

Injectable Steroid for Muscle Growth
Prime Substance: Testosterone Cypionate
Produced by: Dragon Pharmaceutical
10 mL Sterile Multi-dose Vial (250 mg/mL)

Enantat 400

Basal Component: Testosterone Enanthate
Producer: Dragon Pharmaceuticals
Package: 10 mL vial (400 mg/mL)